310 related articles for article (PubMed ID: 34991708)
1. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.
Kuang C; Park Y; Augustin RC; Lin Y; Hartman DJ; Seigh L; Pai RK; Sun W; Bahary N; Ohr J; Rhee JC; Marks SM; Beasley HS; Shuai Y; Herman JG; Zarour HM; Chu E; Lee JJ; Krishnamurthy A
Clin Epigenetics; 2022 Jan; 14(1):3. PubMed ID: 34991708
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
Haag GM; Springfeld C; Grün B; Apostolidis L; Zschäbitz S; Dietrich M; Berger AK; Weber TF; Zoernig I; Schaaf M; Waberer L; Müller DW; Al-Batran SE; Halama N; Jaeger D
Eur J Cancer; 2022 May; 167():112-122. PubMed ID: 35427833
[TBL] [Abstract][Full Text] [Related]
4. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
Kim DW; Tan E; Zhou JM; Schell MJ; Martinez M; Yu J; Carballido E; Mehta R; Strosberg J; Imanirad I; Kim RD
Br J Cancer; 2021 May; 124(11):1803-1808. PubMed ID: 33828254
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
7. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
8. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Garralda E; Sukari A; Lakhani NJ; Patnaik A; Lou Y; Im SA; Golan T; Geva R; Wermke M; de Miguel M; Palcza J; Jha S; Chaney M; Abraham AK; Healy J; Falchook GS
ESMO Open; 2022 Dec; 7(6):100639. PubMed ID: 36493599
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
Yarchoan M; Huang CY; Zhu Q; Ferguson AK; Durham JN; Anders RA; Thompson ED; Rozich NS; Thomas DL; Nauroth JM; Rodriguez C; Osipov A; De Jesus-Acosta A; Le DT; Murphy AG; Laheru D; Donehower RC; Jaffee EM; Zheng L; Azad NS
Cancer Med; 2020 Feb; 9(4):1485-1494. PubMed ID: 31876399
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.
Gallois C; Emile JF; Kim S; Monterymard C; Gilabert M; Bez J; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Coriat R; Legoux JL; Hautefeuille V; Phelip JM; Lecomte T; Sokol H; Capron C; Randrian V; Lepage C; Lomenie N; Kurtz C; Taieb J; Tougeron D
Dig Liver Dis; 2021 Oct; 53(10):1254-1259. PubMed ID: 34215534
[TBL] [Abstract][Full Text] [Related]
11. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186.
Herting CJ; Farren MR; Tong Y; Liu Z; O'Neil B; Bekaii-Saab T; Noonan A; McQuinn C; Mace TA; Shaib W; Wu C; El-Rayes BF; Shahda S; Lesinski GB
Cancer Immunol Immunother; 2021 Nov; 70(11):3337-3348. PubMed ID: 34160684
[TBL] [Abstract][Full Text] [Related]
12. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.
Papadatos-Pastos D; Yuan W; Pal A; Crespo M; Ferreira A; Gurel B; Prout T; Ameratunga M; Chénard-Poirier M; Curcean A; Bertan C; Baker C; Miranda S; Masrour N; Chen W; Pereira R; Figueiredo I; Morilla R; Jenkins B; Zachariou A; Riisnaes R; Parmar M; Turner A; Carreira S; Yap C; Brown R; Tunariu N; Banerji U; Lopez J; de Bono J; Minchom A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35717027
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Theelen WSME; Chen D; Verma V; Hobbs BP; Peulen HMU; Aerts JGJV; Bahce I; Niemeijer ALN; Chang JY; de Groot PM; Nguyen QN; Comeaux NI; Simon GR; Skoulidis F; Lin SH; He K; Patel R; Heymach J; Baas P; Welsh JW
Lancet Respir Med; 2021 May; 9(5):467-475. PubMed ID: 33096027
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.
Yoshino T; Andre T; Kim TW; Yong WP; Shiu KK; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Alcaide-Garcia J; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Le DT; Adachi N; Fogelman D; Marinello P; Diaz LA
Cancer Sci; 2023 Mar; 114(3):1026-1036. PubMed ID: 36369901
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
Monge C; Xie C; Myojin Y; Coffman K; Hrones DM; Wang S; Hernandez JM; Wood BJ; Levy EB; Juburi I; Hewitt SM; Kleiner DE; Steinberg SM; Figg WD; Redd B; Homan P; Cam M; Ruf B; Duffy AG; Greten TF
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754451
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Razak AR; Cleary JM; Moreno V; Boyer M; Calvo Aller E; Edenfield W; Tie J; Harvey RD; Rutten A; Shah MA; Olszanski AJ; Jäger D; Lakhani N; Ryan DP; Rasmussen E; Juan G; Wong H; Soman N; Smit MD; Nagorsen D; Papadopoulos KP
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046621
[TBL] [Abstract][Full Text] [Related]
20. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L
Eur J Cancer; 2019 Feb; 108():120-128. PubMed ID: 30654297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
